keyword
MENU ▼
Read by QxMD icon Read
search

Eylea

keyword
https://www.readbyqxmd.com/read/28297035/short-term-effects-of-early-switching-to-ranibizumab-or-aflibercept-in-diabetic-macular-edema-cases-with-non-response-to-bevacizumab
#1
Mohammed Ashraf, Ahmed A R Souka, Hassan ElKayal
BACKGROUND AND OBJECTIVES: To study the effect of early switching to ranibizumab (Lucentis; Genentech, South San Francisco, CA) or aflibercept (Eylea; Regeneron, Tarrytown, NY) in cases of diabetic macular edema (DME) that have shown no response to bevacizumab (Avastin; Genentech, South San Francisco, CA). PATIENTS AND METHODS: A retrospective study involving 59 eyes of 45 patients with DME previously treated with bevacizumab. Patients were switched either to ranibizumab or aflibercept...
March 1, 2017: Ophthalmic Surgery, Lasers & Imaging Retina
https://www.readbyqxmd.com/read/28279730/efficacy-of-aflibercept-eylea-%C3%A2-on-inhibition-of-human-vegf-in-vitro
#2
M Schicht, K Hesse, H Schröder, E Naschberger, W Lamprecht, F Garreis, F P Paulsen, L Bräuer
INTRODUCTION: Pathological formation of blood vessels plays a key role in the growth and metastasis of tumors and also in several serious ophthalmological diseases such as wet age-related macular degeneration (AMD) or diabetic retinopathy. In AMD treatment, aflibercept (tradename EYLEA(®)) is used to deactivate the underlying pathological neovascularisation. Aflibercept is a recombinant fusion protein which binds to vascular endothelial growth factor (VEGF) receptors, thereby inhibiting VEGF pathway activation...
March 7, 2017: Annals of Anatomy, Anatomischer Anzeiger: Official Organ of the Anatomische Gesellschaft
https://www.readbyqxmd.com/read/28195620/significant-bilateral-response-in-diabetic-macular-edema-after-single-unilateral-intravitreal-aflibercept-injection
#3
Ehsan Rahimy, Omondi Nyong'o, Theodore Leng
A 61-year-old patient with bilateral, treatment-naïve, diffuse diabetic macular edema (DME) that had been progressing during the previous 12 months received a single intravitreal injection of aflibercept (Eylea; Regeneron, Tarrytown, NY) to the left eye. At 2-week follow-up, noticeable bilateral improvement of the DME was observed by spectral-domain optical coherence tomography imaging with commensurate improvement of visual acuity to 20/30 bilaterally. [Ophthalmic Surg Lasers Imaging Retina. 2017;48:167-169...
February 1, 2017: Ophthalmic Surgery, Lasers & Imaging Retina
https://www.readbyqxmd.com/read/28060392/intravitreal-aflibercept-for-neovascular-polypoidal-choroidal-vasculopathy-in-a-predominantly-non-asian-population-rival-results
#4
Amina Farooq, Heather Frazier, William B Marcus, Chelsea Fechter, Harinderjit Singh, Dennis M Marcus
BACKGROUND AND OBJECTIVE: To evaluate safety and efficacy of intravitreal aflibercept (Eylea; Regeneron, Tarrytown, NY) injection (IAI) for the treatment of neovascular polypoidal choroidal vasculopathy (PCV) in a predominantly non-Asian population. PATIENTS AND METHODS: This was an open-label, prospective, unmasked, nonrandomized clinical trial. Twenty eyes with neovascular PCV received monthly 2.0 mg IAI for 3 months followed by mandatory IAI every 2 months for 12 months...
January 1, 2017: Ophthalmic Surgery, Lasers & Imaging Retina
https://www.readbyqxmd.com/read/27977841/polypoidal-choroidal-vasculopathy-occurring-in-the-context-of-large-colloid-drusen
#5
Thibaud Mathis, Laurent Kodjikian, Martine Mauget-Faÿsse, Audrey Feldman
The authors report, for the first time, an association between large colloid drusen (LCD) and choroidal neovascularization in a 58-year-old man. Multimodal imaging confirmed the diagnosis of LCD in both eyes and polypoidal choroidal vasculopathy in the left eye. The patient was treated with monthly intravitreal injections of aflibercept (Eylea; Regeneron, Tarrytown, NY). The authors hypothesize that these deposits are probably associated with retinal pigment epithelium dysfunction and could thus lead to delayed neovascularization and atrophy...
December 1, 2016: Ophthalmic Surgery, Lasers & Imaging Retina
https://www.readbyqxmd.com/read/27721789/treatment-of-retinitis-pigmentosa-associated-cystoid-macular-oedema-using-intravitreal-aflibercept-eylea-despite-minimal-response-to-ranibizumab-lucentis-a-case-report
#6
Stacey A Strong, Avinash Gurbaxani, Michel Michaelides
BACKGROUND: We present an interesting case of bilateral retinitis pigmentosa (RP)-associated cystoid macular oedema that responded on two separate occasions to intravitreal injections of aflibercept, despite previously demonstrating only minimal response to intravitreal ranibizumab. This unique case would support a trial of intravitreal aflibercept for the treatment of RP-associated cystoid macular oedema. CASE PRESENTATION: A 38-year-old man from Dubai, United Arab Emirates, presented to the UK with a 3-year history of bilateral RP-associated cystoid macular oedema...
May 2016: Case Reports in Ophthalmology
https://www.readbyqxmd.com/read/27631479/aflibercept-for-diabetic-macular-edema-in-eyes-previously-treated-with-ranibizumab-and-or-bevacizumab-may-further-improve-macular-thickness
#7
Chirag P Shah, Jeffrey S Heier
BACKGROUND AND OBJECTIVE: To evaluate the short-term anatomic and visual outcomes after aflibercept (Eylea; Regeneron, Tarrytown, NY) in eyes with diabetic macular edema (DME) previously treated with ranibizumab (Lucentis; Genentech, South San Francisco, CA) and/or bevacizumab (Avastin; Genentech, South San Francisco, CA). PATIENTS AND METHODS: A single-center, retrospective, noncomparative study of 30 eyes in 23 patients with DME treated with prior ranibizumab and/or bevacizumab before switching to aflibercept...
September 1, 2016: Ophthalmic Surgery, Lasers & Imaging Retina
https://www.readbyqxmd.com/read/27615995/study-of-stability-and-biophysical-characterization-of-ranibizumab-and-aflibercept
#8
M R Moreno, T S Tabitha, J Nirmal, K Radhakrishnan, C H Yee, S Lim, S Venkatraman, R Agrawal
The anti-vascular endothelial growth factor (VEGF) agents such as ranibizumab (Lucentis®) and aflibercept (EyLea®) are currently used as monthly or bimonthly intravitreal injections to treat potentially retinal diseases such as wet age-related macular degeneration (AMD) or diabetic macular edema (DME). Because of the complications associated with repeated intra-vitreal injections, there is considerable interest in developing a sustained delivery system. The purpose of this study was to examine the stability of both therapeutic proteins under physiological conditions as well as when incorporated into drug delivery systems (DDS)...
November 2016: European Journal of Pharmaceutics and Biopharmaceutics
https://www.readbyqxmd.com/read/27440854/air-entry-into-the-anterior-chamber-post-intravitreal-injection-of-eylea
#9
Wei Sing Lim, Munir Sikandar, Heather Jackson
An 84-year-old man had air entry into the anterior chamber following intravitreal injection. The air bubble was reabsorbed over time without any complications. No further problems occurred with subsequent intravitreal injections.
July 20, 2016: BMJ Case Reports
https://www.readbyqxmd.com/read/27348433/the-role-of-anti-vegf-therapy-in-the-treatment-of-diabetic-macular-edema
#10
Darius M Moshfeghi, Peter K Kaiser, Stephan Michels, Edoardo Midena, John W Kitchens, Jonathan L Prenner, Carl D Regillo, Elias Reichel
Diabetic retinopathy (DR) is the leading cause of blindness among working-age adults. DR often leads to diabetic macular edema (DME), which often goes unnoticed until a patient presents with vision loss. However, treatment options and data for DME are continually improving. We know that vascular endothelial growth factor (VEGF) plays a key role in DME progression; therapies that act by inhibiting VEGF production seem to improve visual acuity in patients with DME. Of the anti-VEGF therapies available, two have been approved by the U...
June 2016: Ophthalmic Surgery, Lasers & Imaging Retina
https://www.readbyqxmd.com/read/27348231/aflibercept-as-first-line-therapy-in-patients-with-treatment-na%C3%A3-ve-neovascular-age-related-macular-degeneration-prospective-case-series-analysis-in-real-life-clinical-practice
#11
RANDOMIZED CONTROLLED TRIAL
Patricia Udaondo, David Salom, Salvador García-Delpech, Ángel Cisneros-Lanuza
PURPOSE: To assess the 13-month effectiveness and safety of aflibercept in naïve patients with neovascular age-related macular degeneration (nvAMD) in a real-life clinical setting. METHODS: Thirty-two treatment-naïve patients with nvAMD participated in a prospective two-center study. Patients received intravitreal injections of aflibercept (Eylea®), a loading dose of three monthly injections (2 mg/0.05 ml) every 4 weeks for the first 3 months, followed by intravitreal injections every 2 months...
2016: Ophthalmologica. Journal International D'ophtalmologie
https://www.readbyqxmd.com/read/27327292/macular-telangiectasia-type-1-managed-with-long-term-aflibercept-therapy
#12
Jaclyn L Kovach, Harald Hess, Philip J Rosenfeld
A 60-year-old man diagnosed with macular telangiectasia type 1 (MacTel 1) was treated for 3 years with monthly aflibercept (Eylea; Regeneron, Tarrytown, NY) and serially imaged with spectral-domain optical coherence tomography. When administered monthly, aflibercept appeared to have a beneficial effect on macular edema secondary to MacTel 1. Visual acuity preservation despite minimal chronic macular edema could be attributed to the lack of significant photoreceptor disruption. [Ophthalmic Surg Lasers Imaging Retina...
June 1, 2016: Ophthalmic Surgery, Lasers & Imaging Retina
https://www.readbyqxmd.com/read/27327285/physician-utilization-patterns-for-vegf-inhibitor-drugs-in-the-2012-united-states-medicare-population-bevacizumab-ranibizumab-and-aflibercept
#13
Shivani Baisiwala, M Kate Bundorf, Suzann Pershing
BACKGROUND AND OBJECTIVE: To evaluate variation in physician use of vascular endothelial growth factor (VEGF) inhibitors. PATIENTS AND METHODS: Population-based analysis of comprehensive, publicly available 2012 Medicare claims, aggregated by physician specialty and service type - including intravitreal injections of bevacizumab (Avastin; Genentech, South San Francisco, CA), ranibizumab (Lucentis; Genetech, South San Francisco, CA), and aflibercept (Eylea; Regeneron, Tarrytown, NY)...
June 1, 2016: Ophthalmic Surgery, Lasers & Imaging Retina
https://www.readbyqxmd.com/read/27327284/retina-specialists-treating-diabetic-macular-edema-recommend-different-approaches-for-patients-than-they-would-choose-for-themselves
#14
Charles G Miller, Greg Budoff, Karen W Jeng-Miller, Howard F Fine, Daniel B Roth, Jonathan L Prenner
BACKGROUND AND OBJECTIVE: Prior investigation shows retina specialists may select different treatment for age-related macular degeneration for themselves than for a hypothetical patient. The authors sought to investigate whether a similar bias exists for treatment decisions by retina specialists with regard to diabetic macular edema (DME). PATIENTS AND METHODS: Two surveys asked retina specialists to select treatment for hypothetical patients with DME or for themselves...
June 1, 2016: Ophthalmic Surgery, Lasers & Imaging Retina
https://www.readbyqxmd.com/read/27258433/intraocular-pharmacokinetics-of-intravitreal-aflibercept-eylea-in-a-rabbit-model
#15
Sang Jun Park, Yewon Choi, Young Mi Na, Hye Kyoung Hong, Ji Yeon Park, Kyu Hyung Park, Jae Yong Chung, Se Joon Woo
Purpose: We determined the intraocular pharmacokinetic properties of intravitreally injected aflibercept (Eylea) in a rabbit model. Methods: Aflibercept was injected intravitreally in 21 eyes from New Zealand White rabbits. The eyes were enucleated 1, 24, 48, 120, 216, 360, and 720 hours (1, 2, 5, 9, 15, and 30 days, respectively) after injection and immediately frozen at -80°C. The concentrations of aflibercept in the vitreous, aqueous humor, and retina/choroid were determined by performing an indirect enzyme-linked immunosorbent assay, and analyzed to understand the pharmacokinetic properties of the drug...
May 1, 2016: Investigative Ophthalmology & Visual Science
https://www.readbyqxmd.com/read/27236451/safety-and-complications-of-intravitreal-injections-performed-in-an-asian-population-in-singapore
#16
Yanping Xu, Colin S Tan
There has been a rapid rise in the use of intravitreal injections, such as anti-vascular endothelial growth factor (anti-VEGF) agents, performed over the past few years for the treatment of ocular neovascular diseases. This study aims to review the systemic and ocular adverse events among patients treated at a tertiary eye center over a period of 8 years. A retrospective review of all intravitreal injections of anti-VEGF performed over an 8-year period at a tertiary eye care center in Singapore was done. We report the frequency of systemic and ocular adverse events and compared it among the various anti-VEGF agents...
April 2017: International Ophthalmology
https://www.readbyqxmd.com/read/27190127/three-month-outcome-of-intravitreal-ziv-aflibercept-in-eyes-with-diabetic-macular-oedema
#17
Ahmad M Mansour, Chintan Dedhia, Jay Chhablani
PURPOSE: We report the 3-month efficacy of monthly intravitreal ziv-aflibercept in patients with diabetic macular oedema (DME). METHODS: Prospectively, consecutive patients with DME underwent intravitreal injection of 0.05 ml of compounded ziv-aflibercept (1.25 mg) from March 2015 to November 2015. Monitoring of best-corrected visual acuity (BCVA), intraocular inflammation, cataract progression and retinal structure by spectral domain optical coherence tomography was carried out at baseline, 1 week, 1 month, 2 months and 3 months after 3 monthly injections...
May 17, 2016: British Journal of Ophthalmology
https://www.readbyqxmd.com/read/27183554/progressive-release-of-vitreomacular-traction-with-aflibercept
#18
Stephen G Schwartz, Harry W Flynn
A patient with combined diabetic macular edema (DME) and vitreomacular traction (VMT) was treated with a series of intravitreal aflibercept (Eylea; Regeneron, Tarrytown, NY) injections. The VMT progressively released during the course of the five intravitreal injections. This release may have been spontaneous, due to a nonspecific mechanical effect from the injections, or due to a pharmacologic effect from the aflibercept. While treating DME, anti-vascular endothelial growth factor agents may have an additional benefit in releasing VMT...
May 1, 2016: Ophthalmic Surgery, Lasers & Imaging Retina
https://www.readbyqxmd.com/read/27183553/reduction-of-diabetic-macular-edema-in-the-untreated-fellow-eye-following-intravitreal-injection-of-aflibercept
#19
Charles M Calvo, Jayanth Sridhar, Abtin Shahlaee, Allen C Ho
A 59-year-old patient with bilateral worsening diabetic macular edema received intravitreal injection of aflibercept (Eylea; Regeneron, Tarrytown, NY) to the left eye only. On 1-month follow-up, there was noted bilateral improvement of visual acuity and diabetic macular edema on spectral-domain optical coherence tomography imaging, reflecting bilateral effect of unilateral treatment with aflibercept. [Ophthalmic Surg Lasers Imaging Retina. 2016;47:474-476.].
May 1, 2016: Ophthalmic Surgery, Lasers & Imaging Retina
https://www.readbyqxmd.com/read/27183550/factors-associated-with-poor-response-to-aflibercept-after-switching-from-ranibizumab-or-bevacizumab-in-neovascular-age-related-macular-degeneration
#20
Sarah Cheng, Theodore Leng
BACKGROUND AND OBJECTIVE: The purpose of this study was to analyze demographic and ocular features of patients with age-related macular degeneration who failed aflibercept (Eylea; Regeneron, Tarrytown, NY) treatment after switching from ranibizumab (Lucentis; Genentech, South San Francisco, CA) or bevacizumab (Avastin; Genentech, South San Francisco, CA). PATIENTS AND METHODS: Retrospective chart review of patients treated with aflibercept at the Byers Eye Institute from November 2011 to August 2014...
May 1, 2016: Ophthalmic Surgery, Lasers & Imaging Retina
keyword
keyword
1764
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"